Literature DB >> 22971511

The characterization and management of Castleman's disease.

N Zhou1, C W Huang, C Huang, W Liao.   

Abstract

OBJECTIVE: Castleman's disease (CD) is a rare disorder of unknown aetiology characterized by lymph node enlargement. This study evaluated the clinical features, diagnosis and outcomes of surgical treatment in patients with CD.
METHODS: The medical records of 10 patients with histologically confirmed CD who underwent surgery between 2003 and 2008 were retrospectively reviewed. Study endpoints were survival and recurrence.
RESULTS: The age of disease onset ranged from 11 to 63 years (median 38 years). Of the 10 patients included in the study, eight were diagnosed with localized (unicentric) CD and two with multicentric CD. All eight patients with localized (unicentric) CD were asymptomatic. Histological evidence indicated the hyaline vascular form of CD in eight patients and the plasmacytic form in the remaining two patients. The primary treatment was complete surgical resection in nine cases, and these patients were alive with no evidence of recurrence or exacerbation at the time of writing (June 2011).
CONCLUSIONS: Localized (unicentric) CD is usually of the hyaline vascular form and complete surgical excision of the tumour allows full recovery in most cases.

Entities:  

Mesh:

Year:  2012        PMID: 22971511     DOI: 10.1177/147323001204000438

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  6 in total

1.  Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.

Authors:  Xinping Zhou; Juying Wei; Yinjun Lou; Gaixiang Xu; Min Yang; Hui Liu; Liping Mao; Hongyan Tong; Jie Jin
Journal:  Front Med       Date:  2017-04-03       Impact factor: 4.592

2.  Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.

Authors:  Siyu Qian; Mengjie Ding; Huting Hou; Zeyuan Wang; Jieming Zhang; Yue Zhang; Meng Dong; Linan Zhu; Guannan Wang; Wencai Li; Xudong Zhang
Journal:  Front Immunol       Date:  2022-05-17       Impact factor: 8.786

3.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08

4.  Multicentric Castleman's Disease in a Child Revealed by Chronic Diarrhea.

Authors:  Sarra Benmiloud; Sana Chaouki; Samir Atmani; Moustapha Hida
Journal:  Case Rep Pediatr       Date:  2015-02-09

5.  Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.

Authors:  Q Lin; B Fang; H Huang; F Yu; X Chai; Y Zhang; J Zhou; Q Xia; Y Li; Y Song
Journal:  Blood Cancer J       Date:  2015-03-20       Impact factor: 11.037

6.  Video-assisted thoracoscopic surgery is a safe and effective method to treat intrathoracic unicentric Castleman's disease.

Authors:  Yan-Qing Wang; Shan-Qing Li; Feng Guo
Journal:  BMC Surg       Date:  2020-06-10       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.